+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Candidiasis Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 250 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5987572
The global market for Candidiasis Drugs is estimated at US$4.3 Billion in 2023 and is projected to reach US$5.2 Billion by 2030, growing at a CAGR of 3.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the candidiasis drugs market is driven by several factors. Technological advancements in drug development and delivery systems are enabling more efficient and targeted treatments, thus expanding the market. The rising prevalence of candidiasis, particularly among the aging population and those with weakened immune systems, such as HIV patients and cancer patients undergoing chemotherapy, is a significant driver. Additionally, increasing awareness and educational initiatives about fungal infections are prompting early diagnosis and treatment, thereby boosting market demand.

Consumer behavior is also shifting towards seeking medical advice and over-the-counter treatments for recurrent infections, contributing to market growth. Furthermore, strong investment in research and development by pharmaceutical companies, along with supportive regulatory frameworks for fast-track approvals of antifungal drugs, is fostering innovation and expansion in the candidiasis drugs market.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Azoles Drug Class segment, which is expected to reach US$2.7 Billion by 2030 with a CAGR of a 3.1%. The Echinocandins Drug Class segment is also set to grow at 2.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.1 Billion in 2023, and China, forecasted to grow at an impressive 3.0% CAGR to reach $845.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Candidiasis Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Candidiasis Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Candidiasis Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AdvaCare Pharma, Astellas Pharma Inc, Atom Pharma, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

  • AdvaCare Pharma
  • Astellas Pharma Inc
  • Atom Pharma
  • Cadila Pharmaceuticals Ltd.
  • F2G Ltd
  • Gilead Sciences, Inc
  • GlaxoSmithKline (GSK Plc)
  • Matinas BioPharma Holdings, Inc
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc
  • Pfizer Inc
  • Pulmocide Ltd
  • SCYNEXIS, Inc.
  • Viatris
  • Xellia Pharmaceuticals

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Candidiasis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Innovative Antifungal Therapies Propel Growth in Candidiasis Drugs Market
  • Increasing Incidence of Drug-Resistant Strains Expands Addressable Market Opportunity
  • Advancements in Biotechnology and Genomics Strengthen Business Case for Novel Candidiasis Treatments
  • Rising Prevalence of Immunocompromised Conditions Spurs Demand for Effective Candidiasis Medications
  • Telemedicine and Mobile Health Apps Accelerate Demand for Convenient Candidiasis Medications
  • Growing Awareness and Early Diagnosis Throw the Spotlight on Candidiasis Drugs Market
  • Educational Initiatives Propel Growth by Promoting Early Detection and Treatment
  • Focus on Reducing Side Effects Enhances the Business Case for New Antifungal Medications
  • Evolving Drug Delivery Systems Generate Opportunities in the Candidiasis Drugs Market
  • Increasing Healthcare Expenditure Sustains Growth in Demand for Advanced Candidiasis Treatments
  • Innovations in Pharmacogenomics Strengthen Market Position of Personalized Candidiasis Drugs
  • Advancements in Combination Therapies Drive Adoption and Market Growth
  • Rise in Outpatient Treatment Models Propels Demand for Easily Accessible Candidiasis Medications
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Candidiasis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Candidiasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Echinocandins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Echinocandins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Drugs Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Drugs Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
JAPAN
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
CHINA
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
EUROPE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Candidiasis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Candidiasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
FRANCE
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
GERMANY
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Rest of Europe 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Candidiasis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Asia-Pacific 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Candidiasis Drugs by Drug Class - Azoles, Echinocandins and Other Drugs Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of World 16-Year Perspective for Candidiasis Drugs by Drug Class - Percentage Breakdown of Value Sales for Azoles, Echinocandins and Other Drugs Classes for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AdvaCare Pharma
  • Astellas Pharma Inc
  • Atom Pharma
  • Cadila Pharmaceuticals Ltd.
  • F2G Ltd
  • Gilead Sciences, Inc
  • GlaxoSmithKline (GSK Plc)
  • Matinas BioPharma Holdings, Inc
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc
  • Pfizer Inc
  • Pulmocide Ltd
  • SCYNEXIS, Inc.
  • Viatris
  • Xellia Pharmaceuticals

Table Information